Evidence map›Paper›PMID 36152108›Full record

ArticleInvestigational new drugs2022

Optimal threshold of alpha-fetoprotein response in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab.

Nobuharu Tamaki, Toshifumi Tada, Masayuki Kurosaki, Yutaka Yasui, Hironori Ochi, Toshie Mashiba, Azusa Sakamoto, Hiroyuki Marusawa, Ryoichi Narita, Yasushi Uchida and 17 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Investigational new drugs, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors at 16 institutions in 1 country.

Nobuharu TamakiDepartment of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan.
Toshifumi TadaDepartment of Internal Medicine, Himeji Red Cross Hospital, Hyogo, Japan.
Masayuki KurosakiDepartment of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan. kurosakim@gmail.com.
Yutaka YasuiDepartment of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan.
Hironori OchiCenter for Liver-Biliary-Pancreatic Disease, Matsuyama Red Cross Hospital, Ehime, Japan.
Toshie MashibaCenter for Liver-Biliary-Pancreatic Disease, Matsuyama Red Cross Hospital, Ehime, Japan.
Azusa SakamotoDepartment of Gastroenterology and Hepatology, Osaka Red Cross Hospital, Osaka, Japan.
Hiroyuki MarusawaDepartment of Gastroenterology and Hepatology, Osaka Red Cross Hospital, Osaka, Japan.
Ryoichi NaritaDepartment of Gastroenterology, Oita Red Cross Hospital, Oita, Japan.
Yasushi UchidaDepartment of Gastroenterology, Matsue Red Cross Hospital, Shimane, Japan.
Takehiro AkahaneDepartment of Gastroenterology, Ishinomaki Red Cross Hospital, Miyagi, Japan.
Masahiko KondoDepartment of Gastroenterology, Otsu Red Cross Hospital, Shiga, Japan.
Nami MoriDepartment of Gastroenterology, Hiroshima Red Cross Hospital & Atomic-Bomb Survivors Hospital, Hiroshima, Japan.
Shintaro TakakiDepartment of Gastroenterology, Hiroshima Red Cross Hospital & Atomic-Bomb Survivors Hospital, Hiroshima, Japan.
Keiji TsujiDepartment of Gastroenterology, Hiroshima Red Cross Hospital & Atomic-Bomb Survivors Hospital, Hiroshima, Japan.
Haruhiko KobashiDepartment of Gastroenterology, Japanese Red Cross Okayama Hospital, Okayama, Japan.
Atsunori KusakabeDepartment of Gastroenterology, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Aichi, Japan.
Koichiro FurutaDepartment of Gastroenterology, Masuda Red Cross Hospital, Shimane, Japan.
Hirotaka AraiDepartment of Gastroenterology, Maebashi Red Cross Hospital, Gunma, Japan.
Michiko NonogiDepartment of Gastroenterology, Tokushima Red Cross Hospital, Tokushima, Japan.
Chikara OgawaDepartment of Gastroenterology and Hepatology, Takamatsu Red Cross Hospital, Kagawa, Japan.
Takashi SatoDepartment of Gastroenterology, Nasu Red Cross Hospital, Tochigi, Japan.
Takashi TamadaDepartment of Gastroenterology, Takatsuki Red Cross Hospital, Osaka, Japan.
Shinichiro NakamuraDepartment of Internal Medicine, Himeji Red Cross Hospital, Hyogo, Japan.
Chitomi HasebeDepartment of Gastroenterology, Japanese Red Cross Asahikawa Hospital, Hokkaido, Japan.
Kaoru TsuchiyaDepartment of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan.
Namiki IzumiDepartment of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan.
Musashino Red Cross Hospital · JPHiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital · JPHimeji Red Cross Hospital · JPMatsuyama Red Cross Hospital · JPOsaka Red Cross Hospital · JPJapanese Red Cross Asahikawa Hospital · JPJapanese Red Cross Nagoya Daini Hospital · JPMaebashi Red Cross Hospital · JPMatsue Red Cross Hospital · JPOita Red Cross Hospital · JPOkayama Red Cross General Hospital · JPOtsu Red Cross Hospital · JPTakamatsu Red Cross Hospital · JPTakatsuki Red Cross Hospital · JPTokushima Red Cross Hospital · JPYamaguchi Red Cross Hospital · JP

Funding

Japan Agency for Medical Research and Development JP20fk0210067h0001
6 · The paper itself

Abstract

Alpha-fetoprotein (AFP) response (relative decline in AFP) is associated with imaging response evaluated by response evaluation criteria in solid tumors ver1.1 (RECIST) and survival in treatment for hepatocellular carcinoma (HCC). However, the optimal threshold of AFP response is still unknown, especially in atezolizumab and bevacizumab (Atez/Bev) treatment. In this prospective multicenter study, we aimed to investigate an optimal threshold of AFP response in Atez/Bev treatment. Out of 284 patients with unresectable HCC who were treated with Atez/Bev, 91 patients with AFP ≥ 10 ng/ml were enrolled in the multicenter study. We investigated the relationship between various AFP response thresholds (relative decline ≥ 20%, ≥ 50%, and ≥ 75%) and treatment response and progression-free survival (PFS). An AFP relative decrease of ≥ 50% was associated with an overall response rate (ORR) with an odds ratio (95% confidence interval [CI]) of 5.7 (1.9-17). Disease control rate (DCR) was associated with an AFP relative decrease of ≥ 20%, with a 100% positive predictive value and a 52.0% sensitivity. AFP relative decreases of ≥ 50% and ≥ 20% were significantly associated with PFS with a hazard ratio (HR) of 5.60 (95% CI: 1.6-19, p = 0.006) and a HR of 4.44 (95% CI: 1.9-10, p < 0.001), respectively. AFP response of ≥ 50% and ≥ 20% were related to ORR and DCR, respectively, and both of these responses were also associated with PFS. AFP can be used as a real-time monitor during Atez/Bev treatment and is helpful for treatment optimization.

Indexed as

Carcinoma, HepatocellularLiver Neoplasmsalpha-FetoproteinsAntibodies, Monoclonal, HumanizedBevacizumabHumansProspective Studiesalpha-FetoproteinsAntibodies, Monoclonal, HumanizedatezolizumabBevacizumabAlpha-fetoprotein (AFP)AtezolizumabBevacizumabHepatocellular carcinoma (HCC)

Identifiers

PMID36152108
OpenAlexW4297175545

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.